Skip to content
B
BiotechEdge
Start 14-Day Free Trial

SpringWorks Therapeutics + Merck KGaA

closed

$SWTX acquired by Merck KGaA for $3.4B

Deal Summary

Deal Value
$3.4B
Price/Share
$47
Announced
Mar 10, 2025
Closed
Jun 15, 2025

Fund Positioning

1 of 20 tracked specialist biotech funds held $SWTX — based on SEC 13F filings.

FundSharesValueEntryAt Announcement
OrbiMed Advisors950K$41.9MMar 2025No
← All biotech acquisitions